Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. - Wikidata - wikimedia - TriplyDB

Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

http://www.wikidata.org/entity/Q53656369

about

Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions Molecular markers in the diagnosis of thyroid nodules.The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms.QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study.Diagnostic utility of galectin-3 in thyroid cancer.Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma.Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.Computerized nuclear morphometry in the diagnosis of thyroid lesions with predominant follicular pattern.Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy.Thyroid regeneration: characterization of clear cells after partial thyroidectomy Risk Factors for Distant Metastasis in Patients with Minimally Invasive Follicular Thyroid Carcinoma.Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.Prognostic and predictive factors in endocrine tumours.Pitfalls in thyroid tumour pathology.Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology.Serum biomarkers of papillary thyroid cancer Expression of Cytokeratin-19 and Thyroperoxidase in Relation to Morphological Features in Non-Neoplastic and Neoplastic Lesions of Thyroid.What is New on Thyroid Cancer Biomarkers Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.Biomarker panel diagnosis of thyroid cancer: a critical review.Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology.Molecular pathology of thyroid tumors: diagnostic and prognostic relevance.Highlighting nuclear membrane staining in thyroid neoplasms with emerin: review and diagnostic utility.Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus.Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma.Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.Diagnostic and prognostic markers in differentiated thyroid cancer.Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules.Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer.Classification of thyroid follicular lesions based on nuclear texture features--lesion size matters.HBME-1 expression in differentiated thyroid carcinoma and its correlation with the ultrasonic manifestation of thyroid.Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.[Nodule diagnosed as follicular patterned lesion: are biomarkers the promise?].

P2860

Q21090550-ADD3881C-2151-4028-A23A-91010C58859D Q27687147-AFCB09A9-491C-4C3B-8931-3CFB36016D39 Q30488923-AB898E20-0F3C-4B79-B4FB-518BC4810062 Q33422171-8BC35D30-0568-4F61-8C66-14E875F4833C Q33816239-42C4FFD7-69E3-46A3-912C-E612E5D43A85 Q34167262-D8F68460-4F60-4D84-A79A-1DA420842AF7 Q34378203-78E03D93-B50D-4861-BDB4-5867D618A374 Q34733218-40CABA0C-EB1B-4336-860F-78EEEA1A97E4 Q35125481-855FAE6C-EA6D-4C94-B23D-8D8A1C15655C Q35198957-F8EC311B-9D04-425B-8D07-AD8CE015517E Q35532196-DBAA07E2-3984-40AA-A95E-1FA40CBE08DA Q35572950-83B12201-1346-4998-8192-00BB91E4621A Q35690041-DD18B45C-CFCC-444B-A79E-3A954AA7C333 Q35731026-9B67A95C-2129-4FC3-8D9F-AC192DB3C955 Q35920746-38B1171B-6DBB-453C-9999-9884809C4986 Q36015365-878D6B74-6A07-4247-BF4A-9BD240E5921D Q36219430-84560D39-68B5-4D50-A4AB-8CFFE9005E77 Q36471713-77D7491E-EFA7-488D-A420-128911DF81ED Q36552048-7B7429EE-6339-4281-868C-79552C47FD39 Q36612077-95EBED41-65EB-4213-9757-5EFD84D7A287 Q36834893-E918F645-4B0F-4B22-9F4A-D26C21CB083F Q37132464-083125C1-546A-4B9D-A2AD-06B490C59031 Q37207279-4FE14798-A2A2-4BDD-B46C-9EE8A65ADB6A Q37221063-86988A01-553C-45FA-BEAD-66DBB70729F7 Q37256811-7EE67C9D-5270-424D-8931-E06283D926D8 Q37536948-EC09A49D-F89D-4C91-8B03-A6FD7C5E607E Q37756406-5EA860F4-7BF1-4DD3-BEEC-F5C114881C69 Q38014369-072286A6-BF42-4C3D-919B-409CE6999483 Q38119437-609877DD-4CDA-4B93-B2B5-503D1B23729E Q38388372-33FE91FE-C21D-495C-834C-68C2681209C3 Q38404012-AE8E7E57-57C9-4DD9-B1ED-BE28E5AF38E8 Q38628967-25E9B533-016D-45E6-BCFC-9A9050C8FFAE Q39363188-07979E2F-5B76-4DD4-8173-78D2A29D67EB Q40819992-A7A064BE-8089-4A74-9432-4C5546813458 Q41164512-AF8F73CB-8332-41D4-81E6-164AE2D55350 Q41387787-5004F096-0363-43C5-8C1A-6818A770BD6F Q42665762-5EFDEA49-F169-40ED-894E-0F45443ED992 Q46450135-3FEED3C0-BC47-4D15-B653-D5727C2A3ADE Q46539617-54C21413-7A67-458C-9145-2D7281EE2EAD Q46985000-C7CBEE31-E043-421B-AF5C-8F121F1B5E96

P2860

Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

http://www.wikidata.org/entity/Q53656369

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Usefulness of HBME-1, cytokera ...... agnosis of thyroid malignancy.

@en

Usefulness of HBME-1, cytokera ...... agnosis of thyroid malignancy.

@nl

type

label

Usefulness of HBME-1, cytokera ...... agnosis of thyroid malignancy.

@en

Usefulness of HBME-1, cytokera ...... agnosis of thyroid malignancy.

@nl

prefLabel

Usefulness of HBME-1, cytokera ...... agnosis of thyroid malignancy.

@en

Usefulness of HBME-1, cytokera ...... agnosis of thyroid malignancy.

@nl

P1433

Q53656369-F0AF61E9-2EB8-4DF7-A103-132AB52B69DE

P1476

Q53656369-BA0E92BE-08C2-475F-807D-4A712598B314

P2093

Q53656369-1FEC96E3-6BD1-46ED-9EB4-FA83E7B993D1

Q53656369-738DE49E-ED81-489F-A47F-1818D968D40E

Q53656369-85923038-69D7-4AA3-86BC-595BFDC81356

Q53656369-9F035DBB-A48F-470A-87C1-37D1C532E203

Q53656369-DFACE867-0CA5-46E8-BBF3-46AB47DB0AF1

P2860

Q53656369-09346657-77E1-469F-83B9-15986A307F9E

Q53656369-221797DC-D4FD-41AF-8661-A83438C3F2CB

Q53656369-34F45367-34B1-45E5-9A2D-9BB52251A1AB

Q53656369-86720254-31B2-4351-83C9-22C60861C434

Q53656369-91DF8EBB-302E-4973-BF9E-151D269BD364

Q53656369-A7C71347-1D51-46AC-AF77-71981F4FE0A6

Q53656369-B6F594CE-02CF-4FC0-A7BB-1EA881047B02

Q53656369-CE1B1D64-957A-42C4-9875-B3749843832C

Q53656369-E3E64314-8B4C-4C62-900B-964B0D36D884

P304

Q53656369-6C695DB5-15A5-4D22-B07B-905927C1B510

P31

Q53656369-8C2CF2B8-2BCE-4068-84E5-14ADDB3FB1BA

P356

Q53656369-7090FDB6-53C5-4C8A-9E50-109FE5E1E810

P433

Q53656369-8800A468-D8FB-4DC8-B2AD-392A5A2F0675

P478

Q53656369-964628AD-5888-4594-9E33-7A9BADCE1CF7

P50

Q53656369-91E1DBC2-C2BF-46AB-AF60-DD8917722C07

P577

Q53656369-2754D601-7E06-4E55-934C-ED2ED34C04FD

P5875

Q53656369-AF0B0E0E-F4EE-411B-991F-7D0083E3EF01

P698

Q53656369-FDEAC5C1-6990-4DFF-9003-EFEC38BF4A3B

P356

J.1365-2559.2005.02221.X

P1433

P1476

Usefulness of HBME-1, cytokera ...... agnosis of thyroid malignancy.

@en

P2093

Assumpção LV

http://www.w3.org/2001/XMLSchema#string

Ferreira AP

http://www.w3.org/2001/XMLSchema#string

Ward LS

http://www.w3.org/2001/XMLSchema#string

de Matos PS

http://www.w3.org/2001/XMLSchema#string

de Oliveira Facuri F

http://www.w3.org/2001/XMLSchema#string

P2860

RET/PTC rearrangement in thyroid tumors

Interpretation of RET immunostaining in follicular lesions of the thyroid.

Hyalinizing trabecular tumors of the thyroid: a variant of papillary carcinoma?

Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.

Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions.

Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma.

Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.

Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma

Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens

P304

391-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2559.2005.02221.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7584925

http://www.w3.org/2001/XMLSchema#string

P698

16178894

http://www.w3.org/2001/XMLSchema#string